Key result
Aldosterone-targeted therapy achieves ~87% treatment response in low-renin hypertension regardless of captopril challenge interpretation.
Why the study?
Primary aldosteronism is a distinct cause of low-renin hypertension, but distinguishing between the two conditions by leveraging the physiological effects of ACE inhibition required investigation.
Does empirical aldosterone-targeted therapy provide similar benefits to patients with low-renin hypertension regardless of captopril challenge test interpretation?
Cohort (n=756)
Does empirical aldosterone-targeted therapy provide similar benefits to patients with low-renin hypertension regardless of captopril challenge test interpretation?
Empirical aldosterone-directed therapy for patients with low-renin hypertension suspected of having primary aldosteronism provides high treatment response rates regardless of captopril challenge test results, suggesting it may be an alternative to laborious diagnostics.
Answers are grounded in this paper and cite their sources.
Supports empirical aldosterone-targeted therapy in low-renin hypertension; leaves open whether captopril challenge testing refines selection.
BACKGROUND: Primary aldosteronism (PA) is a distinct cause of low-renin hypertension (LRH), characterized by inappropriate aldosterone production. We investigated the distinction between LRH and PA by leveraging the physiological effects of angiotensin-converting enzyme inhibition. METHODS: We conducted a retrospective cohort study including 756 patients with LRH who underwent a captopril challenge test (CCT) for evaluation of PA. The distinction between PA and LRH was assessed using 4 CCT criteria: (1) Post-CCT plasma renin activity <1 ng/mL per hour and plasma aldosterone concentration decrease <30%; (2) Post-CCT aldosterone-to-renin ratio (ARR) >30 ng/dL per ng/mL per hour; (3) Post-CCT plasma renin activity <1 ng/mL per hour; and (4) Post-CCT plasma aldosterone concentration >11 ng/dL. Longitudinal outcomes following aldosterone-targeted therapy were assessed using the Primary Aldosteronism Surgery Outcome and Primary Aldosteronism Medical Outcome criteria. RESULTS: There was a continuous spectrum of nonsuppressible aldosterone production post-CCT. When interpreting CCT results based on both renin and aldosterone responses (criteria 1 or 2), 57.8% to 66.3% of patients were classified as having PA. In contrast, when based on aldosterone or renin responses alone (criteria 3 or 4), 82.5% to 95.1% of patients were classified as having PA. Complete or partial treatment response rates following aldosterone-targeted therapy were high, ranging from 86.5% to 91.7%, regardless of CCT interpretation. CONCLUSIONS: These findings highlight the blurred distinction between LRH and PA. Although persistently suppressed renin, or elevated aldosterone, following captopril facilitated the maximum capture of PA cases, the implementation of aldosterone-targeted therapy provided similar benefits to all patints, regardless of CCT interpretation. Empirical aldosterone-directed therapy for patients with LRH suspected of having PA may be an appropriate alternative to laborious diagnostics to confirm PA.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (2025) conducted a cohort in Low-renin hypertension (n=756). Captopril challenge test and aldosterone-targeted therapy was evaluated on Classification of primary aldosteronism and treatment response following aldosterone-targeted therapy. Aldosterone-targeted therapy yielded high complete or partial treatment response rates (86.5% to 91.7%) in patients with low-renin hypertension, regardless of captopril challenge test interpretation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: